<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Infliximab</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Infliximab">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Infliximab</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Infliximab</b>, a chimeric monoclonal antibody, sold under the brand name <b>Remicade</b> among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease.<span class="mw-ref" id="cite_ref-AHFS2019_2-0"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is given by slow injection into a vein, typically at six- to eight-week intervals.<span class="mw-ref" id="cite_ref-AHFS2019_2-1"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Infliximab</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Infliximab_structure2.jpg" tppabs="https://ptable.com/wiki/compounds/I/m/Infliximab_structure2.jpg" data-file-width="725" data-file-height="515" data-file-type="bitmap" height="156" width="220"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Monoclonal antibody</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Type</th><td>Whole antibody</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Source</th><td>Chimeric (mouse/human)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Target</th><td><a href="Tumor_necrosis_factors.htm" tppabs="https://ptable.com/wiki/compounds/A/Tumor_necrosis_factors" title="Tumor necrosis factors" class="mw-redirect">TNF</a></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Remicade, Remsima, Inflectra, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>infliximab-abda, infliximab-axxq, infliximab-dyyb, infliximab-qbtx</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/infliximab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/infliximab.html'" tppabs="https://www.drugs.com/monograph/infliximab.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Infliximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Infliximab'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Infliximab" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Infliximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Infliximab'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Infliximab" class="external text external">Infliximab</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Infliximab&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Infliximab&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Infliximab&SearchType=BasicSearch" class="external text external">Infliximab</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>C<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-0"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>N (Not classified yet)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-1"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Intravenous (IV)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L04AB02<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L04AB02  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L04AB02'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L04AB02" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">CA</abbr></small>:<span> </span> ℞-only<span> </span></li>
<li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li>
<li><small><abbr class="country-name">EU</abbr>:</small><span> </span>Rx-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>92% (IV, if 8% left in the syringe)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>reticuloendothelial system</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>9.5 days</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=170277-31-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=170277-31-3'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=170277-31-3" class="external text external">170277-31-3</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00065  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00065'" tppabs="https://www.drugbank.ca/drugs/DB00065" class="external text external">DB00065</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=B72HH48FLU  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=B72HH48FLU'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=B72HH48FLU" class="external text external">B72HH48FLU</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D02598  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D02598'" tppabs="https://www.kegg.jp/entry/D02598" class="external text external">D02598</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201581  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201581'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201581" class="external text external">ChEMBL1201581</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID9040504  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID9040504'" tppabs="https://comptox.epa.gov/dashboard/DTXSID9040504" class="external text external">DTXSID9040504</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>6428</sub><span>H</span><sub>9912</sub><span>N</span><sub>1694</sub><span>O</span><sub>1987</sub><span>S</span><sub>46</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">144<span style="margin-left:.25em;">190</span>.64</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458271995&page2=Infliximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458271995&page2=Infliximab'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458271995&page2=Infliximab" class="external text external">(verify)</a></span></span></td></tr></tbody></table>


<p>Common side effects include infections, acute infusion reactions, and abdominal pain.<span class="mw-ref" id="cite_ref-AHFS2019_2-2"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Infliximab is a chimeric monoclonal antibody biologic. It works by binding to TNF-α. TNF-α is a chemical messenger (cytokine) and a key part of the autoimmune reaction. In rheumatoid arthritis, infliximab seems to work by preventing TNF-α from binding to its receptor in the cell.</p>


<p>Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are monoclonal antibodies and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a "chimeric monoclonal antibody".</p>

<p>Infliximab was approved for medical use in the United States in 1998,<span class="mw-ref" id="cite_ref-AHFS2019_2-3"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> and in the European Union in August 1999.<span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Infliximab biosimilars have been approved in the EU (2013), in Japan (2014), and in the United States (2016, 2017, 2019).<span class="mw-ref" id="cite_ref-Renflexis_approval_4-0"><a href="#cite_note-Renflexis_approval-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Ixifi_approval_5-0"><a href="#cite_note-Ixifi_approval-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Avsola_approval_6-0"><a href="#cite_note-Avsola_approval-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>
<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><meta property="mw:PageProp/toc"></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Crohn's_disease">Crohn's disease</h3></summary>
    
<p>Three phenotypes, or categories of disease, are present in Crohn's disease: stricturing disease (which causes narrowing of the bowel), penetrating disease (which causes fistulae or abnormal connections of the bowel), and inflammatory disease (which primarily causes inflammation).<span class="mw-ref" id="cite_ref-phenotypes_7-0"><a href="#cite_note-phenotypes-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Fistulizing_disease">Fistulizing disease</h4></summary>
    
<p>Infliximab was first used for closure of fistulae in Crohn's disease in 1999. In a 94-patient, phase II clinical trial, the researchers showed Infliximab was effective in closing fistulae between the skin and bowel in 56-68% of patients.<span class="mw-ref" id="cite_ref-Present_8-0"><a href="#cite_note-Present-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span>  A large, 296-patient Phase III clinical trial called the ACCENT 2 trial showed infliximab was additionally beneficial in maintaining closure of fistulae, with almost two-thirds of all patients treated with the three initial doses of infliximab having a fistula response after 14 weeks, and 36% of patients maintaining closure of fistulae after a year, compared with 19% who received placebo therapy.  This final trial resulted in the FDA approval of the drug to treat fistulizing disease.<span class="mw-ref" id="cite_ref-ACCENT2_9-0"><a href="#cite_note-ACCENT2-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Inflammatory_disease">Inflammatory disease</h4></summary>
    
<p>Infliximab has been used to induce and maintain remission in inflammatory Crohn's disease.  The ACCENT 1 trial,  a large, multicentre trial, found 39 to 45% of patients treated with infliximab, who had an initial response to it, maintained remission after 30 weeks, compared with 21% who received placebo treatment.  It also showed a mean maintenance of remission from 38 to 54 weeks compared with 21 weeks for patients who received placebo treatment.<span class="mw-ref" id="cite_ref-ACCENT1_10-0"><a href="#cite_note-ACCENT1-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>Crohn's patients have flares of their disease between periods of disease quiescence.  Severe flares are usually treated with <a href="Prednisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednisone" title="Prednisone">steroid</a> medications to obtain remission, but steroids have many undesirable side effects, so some gastroenterologists are now advocating the use of infliximab as the first drug to try to get patients into remission.  This has been called the top-down approach to treatment.<span class="mw-ref" id="cite_ref-topdown_11-0"><a href="#cite_note-topdown-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Ulcerative_colitis">Ulcerative colitis</h3></summary>
    
<p>Infliximab targets TNF, thought to be more related to Th1 cytokines.  Ulcerative colitis was thought to be a Th2 disease, and infliximab would be of limited use.  However, patients with ulcerative colitis have begun to be treated with infliximab on the basis of two large clinical trials conducted in 2005 by Paul Rutgeerts and William Sandborn.  The Acute ulcerative Colitis Treatment trials (ACT1 and ACT2) to evaluate the utility of infliximab in ulcerative colitis showed 44-45% of patients treated with infliximab for a year maintained a response to the medication, compared with 21% of patients who were treated with placebo medication.  At two months, the response was 61-69% for patients treated with infliximab, and 31% for those treated with placebo.<span class="mw-ref" id="cite_ref-ACT_12-0"><a href="#cite_note-ACT-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>

<p>Newer drugs such as Etrolizumab have similar efficacy to Infliximab with less adverse effects for treatment of ulcerative colitis.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Psoriatic_arthritis">Psoriatic arthritis</h3></summary>
    
<p>In psoriatic arthritis (PsA), inhibitors of TNF, such as infliximab, improve the signs and symptoms. Several therapies with modest efficacy have been studied in nail psoriasis. Among available agents, higher quality data are available to support the efficacy of <a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclosporine" title="Cyclosporine" class="mw-redirect">cyclosporine</a> and infliximab. Based on studies in AS, the results suggest infliximab, <a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">etanercept</a>, and <a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">adalimumab</a> have the potential to reduce the signs and symptoms of moderate to severely active axial involvement in PsA in patients who have had an inadequate response to NSAID (level 1a, grade A). The anti-TNF agents (infliximab and etanercept; level 1b, grade A) are more effective for the treatment of enthesitis than traditional agents. Results suggest infliximab is effective for the treatment of dactylitis in PsA.<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Other">Other</h3></summary>
    
<p>It was approved for treating ankylosing spondylitis,<span class="mw-ref" id="cite_ref-Maxwell_15-0"><a href="#cite_note-Maxwell-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> psoriatic arthritis, psoriasis, rheumatoid arthritis.<span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>

<p>Infliximab is also prescribed (out of indication) for the treatment of Behçet's disease.<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>

<p>Infliximab is the most frequently used biological agent in treating relapsing polychondritis.<span class="mw-ref" id="cite_ref-Relapsing_polychondritis_18-0"><a href="#cite_note-Relapsing_polychondritis-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> Half of the patients saw benefit from this treatment, and a few other patients experienced infections that in some cases lead to death.<span class="mw-ref" id="cite_ref-Relapsing_polychondritis_18-1"><a href="#cite_note-Relapsing_polychondritis-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span><span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>

<p>There have been numerous case reports of the efficacy of infliximab in various inflammatory skin conditions diseases; the FDA approved infliximab for chronic severe plaque psoriasis in adults in September 2006.<span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>

<p>Infliximab has been used off-label in treating refractory sarcoidosis, where other treatments have not been effective.<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>

<p>Infliximab has been tested in chronic obstructive pulmonary disease (COPD) but there was no evidence of benefit with the possibility of harm.<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>

<p>Infliximab is indicated for steroid refractory checkpoint inhibitor induced colitis, at a dose of 5 to 10<span>&nbsp;</span>mg/kg.<span class="mw-ref" id="cite_ref-Brahmer_23-0"><a href="#cite_note-Brahmer-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    


<p>Infliximab has adverse effects, some life-threatening, common to drugs in the class of TNF inhibiting immunosuppressants (which also includes etanercept (Enbrel) and adalimumab (<a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Humira" title="Humira" class="mw-redirect">Humira</a>)). Some of the most severe are:</p>

<ul><li>serious infections</li>
<li>reactivation of hepatitis B</li>
<li>reactivation of tuberculosis<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></li>
<li>lethal hepatosplenic T-cell lymphoma (generally only when combined with <a href="Mercaptopurine.htm" tppabs="https://ptable.com/wiki/compounds/A/6-mercaptopurine" title="6-mercaptopurine" class="mw-redirect">6-mercaptopurine</a>)</li>
<li>drug-induced lupus</li>
<li>demyelinating central nervous system disorders</li>
<li>psoriasis and psoriasiform skin lesions</li>
<li>new-onset vitiligo</li></ul>

<p>Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported with infliximab.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> The FDA issued a warning to doctors appearing in the respective product labeling of infliximab instructing them to screen and monitor potential patients more carefully.<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> The FDA issued a warning to doctors that there is an increased risk of lymphoma and other cancers associated with the use of infliximab and other tumor necrosis factor blockers in children and adolescents.<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>

<p>Maintenance therapy with the drug (versus intermittent or sporadic therapy) lessens the likelihood of developing antibodies to infliximab which are known to reduce the efficacy of the drug.  Combination treatment with <a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">methotrexate</a> (an antifolate drug which suppresses the immune system) has been shown to reduce the formation of these antibodies in patients with rheumatoid arthritis<span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span> and combination therapy with other immunosuppressants has been shown to reduce the likelihood of these antibodies being formed in Crohn's disease.<span class="mw-ref" id="cite_ref-ACCENT1_10-1"><a href="#cite_note-ACCENT1-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span>  The use of immunosuppressants may not be necessary in all diseases for which infliximab is indicated, and indiscriminant uses of these other immunosuppressants carry their own risks. Infliximab was studied in monotherapy (without concomitant immunosuppressants such as methotrexate or <a href="Azathioprine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azathioprine" title="Azathioprine">azathioprine</a>) in psoriasis, psoriatic arthritis, and ankylosing spondylitis.<span class="mw-ref" id="cite_ref-Maxwell_15-1"><a href="#cite_note-Maxwell-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> Only its use in rheumatoid arthritis requires the concomitant use of methotrexate by the U.S. Food and Drug Administration (FDA) product labeling; however, the concomitant use of methotrexate in other disease states may help to reduce the body's immune response to the infliximab and increase its duration of efficacy.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    
<p>Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse <a href="Antibody.htm#Heavy_chain" tppabs="https://ptable.com/wiki/compounds/A/Antibody#Heavy_chain" title="Antibody">heavy</a> and <a href="Antibody.htm#Light_chain" tppabs="https://ptable.com/wiki/compounds/A/Antibody#Light_chain" title="Antibody">light</a> chain <a href="Antibody.htm#Immunoglobulin_domains" tppabs="https://ptable.com/wiki/compounds/A/Antibody#Immunoglobulin_domains" title="Antibody">variable regions</a> combined with human heavy and light chain constant regions.<span class="mw-ref" id="cite_ref-Akiho1_29-0"><a href="#cite_note-Akiho1-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span> It has a serum half-life of 9.5 days and can be detected in serum 8 weeks after infusion treatment.<span class="mw-ref" id="cite_ref-Akiho1_29-1"><a href="#cite_note-Akiho1-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span></p>

<p>Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. Infliximab and <a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">adalimumab</a> (another TNF antagonist) are in the subclass of "anti-TNF antibodies" (they are in the form of naturally occurring antibodies), and are capable of neutralizing all forms (extracellular-, transmembrane-, and receptor-bound) TNF-α.<span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span> Etanercept, a third TNF antagonist, is in a different subclass (receptor-construct fusion protein), and, because of its modified form, cannot neutralize receptor-bound TNF-α.<span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span> Additionally, the anti-TNF antibodies <a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">adalimumab</a> and infliximab have the capability of lysing cells involved in the inflammatory process, whereas the receptor fusion protein apparently lacks this capability.<span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span> Although the clinical significance of these differences have not been absolutely proven, <a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">etanercept</a>, has been shown to perform worse than placebo for Crohn's disease. These differences may account for the differential actions of these drugs in both efficacy and side effects.</p>

<p>Infliximab has high specificity for TNF-α, and does not neutralize TNF beta (TNFβ, also called lymphotoxin α), an unrelated cytokine that uses different receptors from TNF-α. Biological activities attributed to TNF-α include induction of proinflammatory cytokines (such as interleukins IL-1 and IL-6), enhancement of leukocyte movement or migration from the blood vessels into the tissues (by increasing the permeability of endothelial layer of blood vessels), and increasing the release of adhesion molecules. Infliximab prevents disease in transgenic mice (a special type of mice biologically engineered to produce a human form of TNF-α and which are used to test the results of these drugs that might be expected in humans). These experimental mice develop arthritis as a result of their production of human TNF-α, and when administered after disease onset, infliximab allows eroded joints to heal.</p>

<p>Other monoclonal antibodies targeting TNF-α are golimumab, <a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">adalimumab</a>, and certolizumab pegol. <a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">Etanercept</a> also binds and inhibits the action of TNF-α, but is not a monoclonal antibody (it is instead a fusion of TNF-receptor and an antibody constant region).<span class="mw-ref" id="cite_ref-33"><a href="#cite_note-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    

<p>The role of TNF as a key player in the development of rheumatoid arthritis was originally demonstrated by George Kollias and colleagues in proof of principle studies in transgenic animal models.<span class="mw-ref" id="cite_ref-pmid1721867_34-0"><a href="#cite_note-pmid1721867-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span><span class="mw-ref" id="cite_ref-pmid26008591_35-0"><a href="#cite_note-pmid26008591-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span></p>

<p>Infliximab was developed by Junming Le (b.1940) and Jan Vilček (b.1933) at New York University School of Medicine and in collaboration with Centocor, (now Janssen Biotech, Inc.)<span class="mw-ref" id="cite_ref-36"><a href="#cite_note-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Marketing">Marketing</h3></summary>
    

<p>Remicade is marketed by Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.) in the United States, Mitsubishi Tanabe Pharma in Japan, <span class="new">Xian Janssen</span> in China, and Schering-Plough (now part of Merck &amp; Co) elsewhere.<span class="mw-ref" id="cite_ref-JNJ_20071106_141812_37-0"><a href="#cite_note-JNJ_20071106_141812-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Biosimilars">Biosimilars</h3></summary>
    


<p>In June 2013, two biosimilar versions (Inflectra and Remsima) were submitted for approval in Europe, by Hospira and Celltrion Healthcare respectively.<span class="mw-ref" id="cite_ref-george2013_38-0"><a href="#cite_note-george2013-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span> Both had a positive opinion from European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for sale in the European Union (EU).<span class="mw-ref" id="cite_ref-39"><a href="#cite_note-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> Celltrion obtained marketing authorization approval (MAA) from 27 EU countries and 3 EEA (European Economic Area) countries by September 2013.<span class="mw-ref" id="cite_ref-40"><a href="#cite_note-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-Remsima_EPAR_41-0"><a href="#cite_note-Remsima_EPAR-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span><span class="mw-ref" id="cite_ref-Inflectra_EPAR_42-0"><a href="#cite_note-Inflectra_EPAR-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> Inflectra was approved for use in the European Union in September 2013,<span class="mw-ref" id="cite_ref-Inflectra_EPAR_42-1"><a href="#cite_note-Inflectra_EPAR-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> and Remsima was approved for use in the European Union in October 2013.<span class="mw-ref" id="cite_ref-Remsima_EPAR_41-1"><a href="#cite_note-Remsima_EPAR-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span></p>

<p>In Japan, Celltrion received marketing authorization for Remsima from Japan's Ministry of Health, Labour and Welfare (MHLW) in July 2014.</p>

<p>In India, Epirus Biopharmaceuticals obtained approval to produce biosimilar infliximab under the brand name "Infimab" (trail name BOW015).<span class="mw-ref" id="cite_ref-43"><a href="#cite_note-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span></p>

<p>The U.S. Food and Drug Administration (FDA) approved Celltrion/Hospira/Pfizer's Inflectra (infliximab-dyyb) in April 2016.<span class="mw-ref" id="cite_ref-44"><a href="#cite_note-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span><span class="mw-ref" id="cite_ref-45"><a href="#cite_note-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span> Although the US brand name is Inflectra, it is marketed in the European Union as Remsima.<span class="mw-ref" id="cite_ref-Remsima_EPAR_41-2"><a href="#cite_note-Remsima_EPAR-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span></p>

<p>The FDA approved Samsung Bioepis Co., Ltd.'s Renflexis (infliximab-abda) in April 2017.<span class="mw-ref" id="cite_ref-Renflexis_approval_4-1"><a href="#cite_note-Renflexis_approval-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>

<p>Biogen released another biosimilar, Flixabi, which was approved in Germany, the UK, and the Netherlands.<span class="mw-ref" id="cite_ref-biib_46-0"><a href="#cite_note-biib-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span> Flixabi was approved for use in the European Union in May 2016.<span class="mw-ref" id="cite_ref-Flixabi_EPAR_47-0"><a href="#cite_note-Flixabi_EPAR-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span></p>

<p>In December 2017, Ixifi (infliximab-qbtx) was approved in the United States.<span class="mw-ref" id="cite_ref-Ixifi_approval_5-1"><a href="#cite_note-Ixifi_approval-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>

<p>Zessly was approved for use in the European Union in May 2018.<span class="mw-ref" id="cite_ref-Zessly_EPAR_48-0"><a href="#cite_note-Zessly_EPAR-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span></p>

<p>In December 2019, Avsola (infliximab-axxq) was approved in the United States.<span class="mw-ref" id="cite_ref-Avsola_approval_6-1"><a href="#cite_note-Avsola_approval-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Availability/affordability">Availability/affordability</h3></summary>
    
<p>In the United States, Infliximab is an expensive medication, costing about <span style="white-space: nowrap">US$900</span> for a 100<span>&nbsp;</span>mg dose, and is covered by almost every US medical insurance plan (though caps on many plans make it possible to be covered for only a subset of treatments in the course of a year). Infliximab is supplied as a sterile, white, lyophilized (freeze-dried) powder,<span class="mw-ref" id="cite_ref-49"><a href="#cite_note-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span> so must be reconstituted and administered by a health care professional, usually in a hospital or office setting.<span class="mw-ref" id="cite_ref-JNJ_20071106_141812_37-1"><a href="#cite_note-JNJ_20071106_141812-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span> For this reason, it is usually covered under major medical insurance rather than prescription drug coverage. The loading regimen for all approved indications occurs at weeks 0, 2, and 6 at the above dosages.<span class="mw-ref" id="cite_ref-JNJ_20071106_141812_37-2"><a href="#cite_note-JNJ_20071106_141812-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span></p>

<p>In the UK, Infliximab is available from the NHS for Crohn's disease treatment provided three criteria are met.<span class="mw-ref" id="cite_ref-50"><a href="#cite_note-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span> Patients should have severe active Crohn's disease with a CDAI score of 300 or more, have not responded to immunomodulating drugs and corticosteroids, and for whom surgery is inappropriate.  Since February 2015, it is also approved for the treatment of ulcerative colitis where other treatments have not worked.<span class="mw-ref" id="cite_ref-51"><a href="#cite_note-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span></p>

<p>In Australia, Infliximab is available through the PBS for Crohn's disease treatment provided the patient has not responded to conventional treatment and is suffering from a severe case of the condition.<span class="mw-ref" id="cite_ref-52"><a href="#cite_note-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span></p>

<p>Infliximab is available in the Republic of Ireland through the HSE's Medical Card and Drug Payment Scheme.</p>

<p>Johnson &amp; Johnson reported in its 2013 annual report, "Remicade (infliximab), accounted for approximately 9.4% of the Company's total revenues for fiscal 2013." <span class="mw-ref" id="cite_ref-53"><a href="#cite_note-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li>Biological therapy for inflammatory bowel disease</li>
<li>Ulcerative Colitis</li>
<li>Crohn's disease</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Drugs.com_pregnancy-1"> <span id="mw-reference-text-cite_note-Drugs.com_pregnancy-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/infliximab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/infliximab.html'" tppabs="https://www.drugs.com/pregnancy/infliximab.html" class="external text external">"Infliximab Use During Pregnancy"</a>. <i>Drugs.com</i>. 2 July 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">13 August</span> 2020</span>.</cite></span></li><li id="cite_note-AHFS2019-2"> <span id="mw-reference-text-cite_note-AHFS2019-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/infliximab-infliximab-dyyb.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/infliximab-infliximab-dyyb.html'" tppabs="https://www.drugs.com/monograph/infliximab-infliximab-dyyb.html" class="external text external">"Infliximab, Infliximab-dyyb Monograph for Professionals"</a>. <i>Drugs.com</i>. American Society of Health-System Pharmacists<span class="reference-accessdate">. Retrieved <span class="nowrap">15 July</span> 2019</span>.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/remicade  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/remicade'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/remicade" class="external text external">"Remicade EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-Renflexis_approval-4"> <span id="mw-reference-text-cite_note-Renflexis_approval-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20190417115642/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190417115642/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761054'" tppabs="https://web.archive.org/web/20190417115642/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761054" class="external text external">"Renflexis: FDA Approved Drug Products"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 17 April 2019. Archived from the original on 17 April 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">6 December</span> 2019</span>.</cite><span class="cs1-maint citation-comment">CS1 maint: unfit url (link)</span> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-Ixifi_approval-5"> <span id="mw-reference-text-cite_note-Ixifi_approval-5" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761072  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761072'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761072" class="external text external">"Ixifi: FDA-Approved Drugs"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 6 December 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191207000754/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761072  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191207000754/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761072'" tppabs="https://web.archive.org/web/20191207000754/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761072" class="external text external">Archived</a> from the original on 7 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">6 December</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-Avsola_approval-6"> <span id="mw-reference-text-cite_note-Avsola_approval-6" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761086  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761086'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761086" class="external text external">"Avsola: FDA-Approved Drugs"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 6 December 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191207000021/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761086  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191207000021/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761086'" tppabs="https://web.archive.org/web/20191207000021/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761086" class="external text external">Archived</a> from the original on 7 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">6 December</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-phenotypes-7"> <span id="mw-reference-text-cite_note-phenotypes-7" class="mw-reference-text"><cite id="CITEREFDubinskyFleshner2003" class="citation journal cs1">Dubinsky MC, Fleshner PP (June 2003). "Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes". <i>Curr Treat Options Gastroenterol</i>. <b>6</b> (3): 183–200. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs11938-003-0001-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs11938-003-0001-1'" tppabs="https://doi.org/10.1007%2Fs11938-003-0001-1" class="external text external">10.1007/s11938-003-0001-1</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12744819  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12744819'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12744819" class="external text external">12744819</a>.</cite></span></li><li id="cite_note-Present-8"> <span id="mw-reference-text-cite_note-Present-8" class="mw-reference-text"><cite id="CITEREFPresentRutgeertsTarganHanauer1999" class="citation journal cs1">Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (May 1999). <a href="javascript:if(confirm('https://pure.uva.nl/ws/files/3156092/7456_77284y.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pure.uva.nl/ws/files/3156092/7456_77284y.pdf'" tppabs="https://pure.uva.nl/ws/files/3156092/7456_77284y.pdf" class="external text external">"Infliximab for the treatment of fistulas in patients with Crohn's disease"</a> <span class="cs1-format">(PDF)</span>. <i>The New England Journal of Medicine</i>. <b>340</b> (18): 1398–405. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJM199905063401804  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJM199905063401804'" tppabs="https://doi.org/10.1056%2FNEJM199905063401804" class="external text external">10.1056/NEJM199905063401804</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10228190  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10228190'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10228190" class="external text external">10228190</a>.</cite></span></li><li id="cite_note-ACCENT2-9"> <span id="mw-reference-text-cite_note-ACCENT2-9" class="mw-reference-text"><cite id="CITEREFSandsAndersonBernsteinChey2004" class="citation journal cs1">Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ (February 2004). "Infliximab maintenance therapy for fistulizing Crohn's disease". <i>The New England Journal of Medicine</i>. <b>350</b> (9): 876–85. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa030815  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa030815'" tppabs="https://doi.org/10.1056%2FNEJMoa030815" class="external text external">10.1056/NEJMoa030815</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14985485  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14985485'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14985485" class="external text external">14985485</a>.</cite></span></li><li id="cite_note-ACCENT1-10"> <span id="mw-reference-text-cite_note-ACCENT1-10" class="mw-reference-text"><cite id="CITEREFHanauerFeaganLichtensteinMayer2002" class="citation journal cs1">Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P (May 2002). "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial". <i>Lancet</i>. <b>359</b> (9317): 1541–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2802%2908512-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2802%2908512-4'" tppabs="https://doi.org/10.1016%2FS0140-6736%2802%2908512-4" class="external text external">10.1016/S0140-6736(02)08512-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12047962  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12047962'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12047962" class="external text external">12047962</a>.</cite></span></li><li id="cite_note-topdown-11"> <span id="mw-reference-text-cite_note-topdown-11" class="mw-reference-text"><cite id="CITEREFHanauer2003" class="citation journal cs1">Hanauer SB (February 2003). "Crohn's disease: step up or top down therapy". <i>Best Pract Res Clin Gastroenterol</i>. <b>17</b> (1): 131–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1053%2Fbega.2003.0361  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1053%2Fbega.2003.0361'" tppabs="https://doi.org/10.1053%2Fbega.2003.0361" class="external text external">10.1053/bega.2003.0361</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12617888  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12617888'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12617888" class="external text external">12617888</a>.</cite></span></li><li id="cite_note-ACT-12"> <span id="mw-reference-text-cite_note-ACT-12" class="mw-reference-text"><cite id="CITEREFRutgeertsSandbornFeaganReinisch2005" class="citation journal cs1">Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF (2005). "Infliximab for induction and maintenance therapy for ulcerative colitis". <i>The New England Journal of Medicine</i>. <b>353</b> (23): 2462–76. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa050516  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa050516'" tppabs="https://doi.org/10.1056%2FNEJMoa050516" class="external text external">10.1056/NEJMoa050516</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16339095  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16339095'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16339095" class="external text external">16339095</a>.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite id="CITEREFMotaghiGhasemi-PirbalutiZabihi2019" class="citation journal cs1">Motaghi, Ehsan; Ghasemi-Pirbaluti, Masoumeh; Zabihi, Mohsen (January 2019). "Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison". <i>Pharmacological Research</i>. <b>139</b>: 120–125. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.phrs.2018.11.003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.phrs.2018.11.003'" tppabs="https://doi.org/10.1016%2Fj.phrs.2018.11.003" class="external text external">10.1016/j.phrs.2018.11.003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30395950  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30395950'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30395950" class="external text external">30395950</a>.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite id="CITEREFKavanaughRitchlin2006" class="citation journal cs1">Kavanaugh AF, Ritchlin CT (July 2006). "Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines". <i>J. Rheumatol</i>. <b>33</b> (7): 1417–21. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16724373  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16724373'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16724373" class="external text external">16724373</a>.</cite></span></li><li id="cite_note-Maxwell-15"> <span id="mw-reference-text-cite_note-Maxwell-15" class="mw-reference-text"><cite id="CITEREFMaxwellZochlingBoonenSingh2015" class="citation journal cs1">Maxwell, LJ; Zochling, J; Boonen, A; Singh, JA; Veras, MM; Tanjong Ghogomu, E; Benkhalti Jandu, M; Tugwell, P; Wells, GA (18 April 2015). <a href="javascript:if(confirm('http://ecite.utas.edu.au/120128  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://ecite.utas.edu.au/120128'" tppabs="http://ecite.utas.edu.au/120128" class="external text external">"TNF-alpha inhibitors for ankylosing spondylitis"</a>. <i>The Cochrane Database of Systematic Reviews</i>. <b>4</b> (4): CD005468. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD005468.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD005468.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD005468.pub2" class="external text external">10.1002/14651858.CD005468.pub2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25887212  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25887212'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25887212" class="external text external">25887212</a>.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text"><cite id="CITEREFBlumenauerJuddWellsBurls2002" class="citation journal cs1">Blumenauer, Barbara BTB; Judd, Maria; Wells, George A; Burls, Amanda; Cranney, Ann; Hochberg, Marc C; Tugwell, Peter; Lopez-Olivo, Maria Angeles (22 July 2002). "Infliximab for the treatment of rheumatoid arthritis". <i>Cochrane Database of Systematic Reviews</i> (3): CD003785. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.cd003785  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.cd003785'" tppabs="https://doi.org/10.1002%2F14651858.cd003785" class="external text external">10.1002/14651858.cd003785</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1465-1858  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1465-1858'" tppabs="https://www.worldcat.org/issn/1465-1858" class="external text external">1465-1858</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12137712  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12137712'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12137712" class="external text external">12137712</a>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite id="CITEREFSfikakis2002" class="citation journal cs1">Sfikakis PP (November 2002). <a href="javascript:if(confirm('http://ard.bmj.com/content/61/suppl_2/ii51.abstract  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://ard.bmj.com/content/61/suppl_2/ii51.abstract'" tppabs="http://ard.bmj.com/content/61/suppl_2/ii51.abstract" class="external text external">"Behçet's disease: a new target for anti-tumour necrosis factor treatment"</a>. <i>Ann. Rheum. Dis</i>. 61 Suppl 2 (Suppl 2): ii51–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fard.61.suppl_2.ii51  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fard.61.suppl_2.ii51'" tppabs="https://doi.org/10.1136%2Fard.61.suppl_2.ii51" class="external text external">10.1136/ard.61.suppl_2.ii51</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766720  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766720'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766720" class="external text external">1766720</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12379622  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12379622'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12379622" class="external text external">12379622</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20150111152344/http://ard.bmj.com/content/61/suppl_2/ii51.abstract  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150111152344/http://ard.bmj.com/content/61/suppl_2/ii51.abstract'" tppabs="https://web.archive.org/web/20150111152344/http://ard.bmj.com/content/61/suppl_2/ii51.abstract" class="external text external">Archived</a> from the original on 11 January 2015.</cite></span></li><li id="cite_note-Relapsing_polychondritis-18"> <span id="mw-reference-text-cite_note-Relapsing_polychondritis-18" class="mw-reference-text"><cite id="CITEREFPuéchalTerrierMouthonCostedoat-Chalumeau2014" class="citation journal cs1">Puéchal X, Terrier B, Mouthon L, Costedoat-Chalumeau N, Guillevin L, Le Jeunne C (March 2014). <a href="javascript:if(confirm('http://www.hal.inserm.fr/inserm-00951203  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.hal.inserm.fr/inserm-00951203'" tppabs="http://www.hal.inserm.fr/inserm-00951203" class="external text external">"Relapsing polychondritis"</a>. <i>Joint, Bone, Spine<span>&nbsp;</span>: Revue du Rhumatisme</i>. <b>81</b> (2): 118–24. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jbspin.2014.01.001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jbspin.2014.01.001'" tppabs="https://doi.org/10.1016%2Fj.jbspin.2014.01.001" class="external text external">10.1016/j.jbspin.2014.01.001</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24556284  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24556284'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24556284" class="external text external">24556284</a>.</cite></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite id="CITEREFKemta_LekpaKrausChevalier2012" class="citation journal cs1">Kemta Lekpa F, Kraus VB, Chevalier X (April 2012). "Biologics in relapsing polychondritis: a literature review". <i>Seminars in Arthritis and Rheumatism</i>. <b>41</b> (5): 712–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.semarthrit.2011.08.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.semarthrit.2011.08.006'" tppabs="https://doi.org/10.1016%2Fj.semarthrit.2011.08.006" class="external text external">10.1016/j.semarthrit.2011.08.006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22071463  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22071463'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22071463" class="external text external">22071463</a>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite id="CITEREFGuptaSkinner2004" class="citation journal cs1">Gupta AK, Skinner AR (2004). "A review of the use of infliximab to manage cutaneous dermatoses". <i>J Cutan Med Surg</i>. <b>8</b> (2): 77–89. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs10227-004-0115-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs10227-004-0115-7'" tppabs="https://doi.org/10.1007%2Fs10227-004-0115-7" class="external text external">10.1007/s10227-004-0115-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15685387  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15685387'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15685387" class="external text external">15685387</a>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite id="CITEREFWijsenbeekCulver2015" class="citation journal cs1">Wijsenbeek, MS; Culver, DA (December 2015). "Treatment of Sarcoidosis". <i>Clinics in Chest Medicine</i>. <b>36</b> (4): 751–67. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ccm.2015.08.015  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ccm.2015.08.015'" tppabs="https://doi.org/10.1016%2Fj.ccm.2015.08.015" class="external text external">10.1016/j.ccm.2015.08.015</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26593147  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26593147'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26593147" class="external text external">26593147</a>.</cite></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite id="CITEREFRennardFogartyKelsenLong2007" class="citation journal cs1">Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J (May 2007). "The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease". <i>Am. J. Respir. Crit. Care Med</i>. <b>175</b> (9): 926–34. doi:<a href="javascript:if(confirm('https://doi.org/10.1164%2Frccm.200607-995OC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1164%2Frccm.200607-995OC'" tppabs="https://doi.org/10.1164%2Frccm.200607-995OC" class="external text external">10.1164/rccm.200607-995OC</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17290043  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17290043'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17290043" class="external text external">17290043</a>.</cite></span></li><li id="cite_note-Brahmer-23"> <span id="mw-reference-text-cite_note-Brahmer-23" class="mw-reference-text"><cite id="CITEREFBrahmerLacchettiSchneiderAtkins2018" class="citation journal cs1">Brahmer, Julie R.; Lacchetti, Christina; Schneider, Bryan J.; Atkins, Michael B.; Brassil, Kelly J.; Caterino, Jeffrey M.; Chau, Ian; Ernstoff, Marc S.; Gardner, Jennifer M.; Ginex, Pamela; Hallmeyer, Sigrun; Holter Chakrabarty, Jennifer; Leighl, Natasha B.; Mammen, Jennifer S.; McDermott, David F.; Naing, Aung; Nastoupil, Loretta J.; Phillips, Tanyanika; Porter, Laura D.; Puzanov, Igor; Reichner, Cristina A.; Santomasso, Bianca D.; Seigel, Carole; Spira, Alexander; Suarez-Almazor, Maria E.; Wang, Yinghong; Weber, Jeffrey S.; Wolchok, Jedd D.; Thompson, John A. (10 June 2018). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621" class="external text external">"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline"</a>. <i>Journal of Clinical Oncology</i>. <b>36</b> (17): 1714–1768. doi:<a href="javascript:if(confirm('https://doi.org/10.1200%2FJCO.2017.77.6385  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1200%2FJCO.2017.77.6385'" tppabs="https://doi.org/10.1200%2FJCO.2017.77.6385" class="external text external">10.1200/JCO.2017.77.6385</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621" class="external text external">6481621</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29442540  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29442540'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29442540" class="external text external">29442540</a>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite id="CITEREFKeaneGershonWiseMirabile-Levens2001" class="citation journal cs1">Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001). "Tuberculosis associated with infliximab, a tumor necrosis factor <span>α</span>–neutralizing agent". <i>N Engl J Med</i>. <b>345</b> (15): 1098–1104. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa011110  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa011110'" tppabs="https://doi.org/10.1056%2FNEJMoa011110" class="external text external">10.1056/NEJMoa011110</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11596589  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11596589'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11596589" class="external text external">11596589</a>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20080704080738/http://www.remicade.com/remicade/global/hcp/healthcare_professionals.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20080704080738/http://www.remicade.com/remicade/global/hcp/healthcare_professionals.html'" tppabs="https://web.archive.org/web/20080704080738/http://www.remicade.com/remicade/global/hcp/healthcare_professionals.html" class="external text external">"Remicade for Healthcare Professionals"</a>. <i>Remicade</i>. Archived from <a href="javascript:if(confirm('http://www.remicade.com/remicade/global/hcp/healthcare_professionals.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.remicade.com/remicade/global/hcp/healthcare_professionals.html'" tppabs="http://www.remicade.com/remicade/global/hcp/healthcare_professionals.html" class="external text external">the original</a> on 4 July 2008.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><a href="javascript:if(confirm('https://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf'" tppabs="https://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf" class="external autonumber external"></a> <a href="javascript:if(confirm('https://web.archive.org/web/20061009085444/https://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20061009085444/https://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf'" tppabs="https://web.archive.org/web/20061009085444/https://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf" class="external text external">Archived</a><span> October 9, 2006, at the </span>Wayback Machine</span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20091115213333/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20091115213333/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm'" tppabs="https://web.archive.org/web/20091115213333/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm" class="external text external">"Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) August 2009"</a>. <i>MedWatch</i>. U.S. Food and Drug Administration (FDA). 31 August 2009. Archived from <a href="javascript:if(confirm('https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalproducts/ucm175843.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalproducts/ucm175843.htm'" tppabs="https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalproducts/ucm175843.htm" class="external text external">the original</a> on 15 November 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">15 November</span> 2009</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><cite id="CITEREFMainiSt_ClairBreedveldFurst1999" class="citation journal cs1">Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (4 December 1999). "Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group". <i>Lancet</i>. <b>354</b> (9194): 1932–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0140-6736%2899%2905246-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0140-6736%2899%2905246-0'" tppabs="https://doi.org/10.1016%2Fs0140-6736%2899%2905246-0" class="external text external">10.1016/s0140-6736(99)05246-0</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10622295  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10622295'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10622295" class="external text external">10622295</a>.</cite></span></li><li id="cite_note-Akiho1-29"> <span id="mw-reference-text-cite_note-Akiho1-29" class="mw-reference-text"><cite id="CITEREFAkihoYokoyamaAbeNakazono2015" class="citation journal cs1">Akiho, Hirotada; Yokoyama, Azusa; Abe, Shuichi; Nakazono, Yuichi; Murakami, Masatoshi; Otsuka, Yoshihiro; Fukawa, Kyoko; Esaki, Mitsuru; Niina, Yusuke (15 November 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644886  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644886'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644886" class="external text external">"Promising biological therapies for ulcerative colitis: A review of the literature"</a>. <i>World Journal of Gastrointestinal Pathophysiology</i>. <b>6</b> (4): 219–227. doi:<a href="javascript:if(confirm('https://doi.org/10.4291%2Fwjgp.v6.i4.219  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4291%2Fwjgp.v6.i4.219'" tppabs="https://doi.org/10.4291%2Fwjgp.v6.i4.219" class="external text external">10.4291/wjgp.v6.i4.219</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/2150-5330  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/2150-5330'" tppabs="https://www.worldcat.org/issn/2150-5330" class="external text external">2150-5330</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644886  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644886'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644886" class="external text external">4644886</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26600980  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26600980'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26600980" class="external text external">26600980</a>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite id="CITEREFChoyPanayi2001" class="citation journal cs1">Choy EH, Panayi GS (March 2001). "Cytokine pathways and joint inflammation in rheumatoid arthritis". <i>The New England Journal of Medicine</i>. <b>344</b> (12): 907–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJM200103223441207  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJM200103223441207'" tppabs="https://doi.org/10.1056%2FNEJM200103223441207" class="external text external">10.1056/NEJM200103223441207</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11259725  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11259725'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11259725" class="external text external">11259725</a>.</cite></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text">Etanercept product labeling</span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text">Etanercept, Adalimumab and Infliximab product labeling</span></li><li id="cite_note-33"> <span id="mw-reference-text-cite_note-33" class="mw-reference-text"><cite id="CITEREFPeppelCrawfordBeutler1991" class="citation journal cs1">Peppel K, Crawford D, Beutler B (1991). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031" class="external text external">"A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity"</a>. <i>J. Exp. Med</i>. <b>174</b> (6): 1483–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1084%2Fjem.174.6.1483  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1084%2Fjem.174.6.1483'" tppabs="https://doi.org/10.1084%2Fjem.174.6.1483" class="external text external">10.1084/jem.174.6.1483</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031" class="external text external">2119031</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1660525  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1660525'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1660525" class="external text external">1660525</a>.</cite></span></li><li id="cite_note-pmid1721867-34"> <span id="mw-reference-text-cite_note-pmid1721867-34" class="mw-reference-text"><cite id="CITEREFKefferProbertCazlarisGeorgopoulos1991" class="citation journal cs1">Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (December 1991). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC453150  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC453150'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC453150" class="external text external">"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis"</a>. <i>The EMBO Journal</i>. <b>10</b> (13): 4025–31. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fj.1460-2075.1991.tb04978.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fj.1460-2075.1991.tb04978.x'" tppabs="https://doi.org/10.1002%2Fj.1460-2075.1991.tb04978.x" class="external text external">10.1002/j.1460-2075.1991.tb04978.x</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC453150  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC453150'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC453150" class="external text external">453150</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1721867  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1721867'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1721867" class="external text external">1721867</a>.</cite></span></li><li id="cite_note-pmid26008591-35"> <span id="mw-reference-text-cite_note-pmid26008591-35" class="mw-reference-text"><cite id="CITEREFBrennerBlaserMak2015" class="citation journal cs1">Brenner D, Blaser H, Mak TW (May 2015). "Regulation of tumour necrosis factor signalling: live or let die". <i>Nat Rev Immunol</i>. <b>15</b> (6): 362–74. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnri3834  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnri3834'" tppabs="https://doi.org/10.1038%2Fnri3834" class="external text external">10.1038/nri3834</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26008591  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26008591'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26008591" class="external text external">26008591</a>.</cite></span></li><li id="cite_note-36"> <span id="mw-reference-text-cite_note-36" class="mw-reference-text"><cite id="CITEREFKnightTrinhLeSiegel1993" class="citation journal cs1">Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P (November 1993). "Construction and initial characterization of a mouse-human chimeric anti-TNF antibody". <i>Mol. Immunol</i>. <b>30</b> (16): 1443–53. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0161-5890%2893%2990106-L  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0161-5890%2893%2990106-L'" tppabs="https://doi.org/10.1016%2F0161-5890%2893%2990106-L" class="external text external">10.1016/0161-5890(93)90106-L</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8232330  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8232330'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8232330" class="external text external">8232330</a>.</cite></span></li><li id="cite_note-JNJ_20071106_141812-37"> <span id="mw-reference-text-cite_note-JNJ_20071106_141812-37" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20110713111255/http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110713111255/http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812'" tppabs="https://web.archive.org/web/20110713111255/http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812" class="external text external">"Remicade Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide"</a> (Press release). Johnson &amp; Johnson. 6 November 2007. Archived from <a href="javascript:if(confirm('http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812'" tppabs="http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812" class="external text external">the original</a> on 13 July 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">14 November</span> 2009</span>.</cite></span></li><li id="cite_note-george2013-38"> <span id="mw-reference-text-cite_note-george2013-38" class="mw-reference-text"><cite id="CITEREFGeorge2013" class="citation news cs1">George, John (28 June 2013). <a href="javascript:if(confirm('http://www.bizjournals.com/philadelphia/news/2013/06/28/biliion-dollar-biotech-drug-may-soon.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.bizjournals.com/philadelphia/news/2013/06/28/biliion-dollar-biotech-drug-may-soon.html'" tppabs="http://www.bizjournals.com/philadelphia/news/2013/06/28/biliion-dollar-biotech-drug-may-soon.html" class="external text external">"Billion-dollar biotech drug may soon have biosimilar competition"</a>. <i>Philadelphia Business Journal</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20130701183938/http://www.bizjournals.com/philadelphia/news/2013/06/28/biliion-dollar-biotech-drug-may-soon.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130701183938/http://www.bizjournals.com/philadelphia/news/2013/06/28/biliion-dollar-biotech-drug-may-soon.html'" tppabs="https://web.archive.org/web/20130701183938/http://www.bizjournals.com/philadelphia/news/2013/06/28/biliion-dollar-biotech-drug-may-soon.html" class="external text external">Archived</a> from the original on 1 July 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">27 June</span> 2013</span>.</cite></span></li><li id="cite_note-39"> <span id="mw-reference-text-cite_note-39" class="mw-reference-text"><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001837.jsp&mid=WC0b01ac058004d5c1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001837.jsp&mid=WC0b01ac058004d5c1'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001837.jsp&mid=WC0b01ac058004d5c1" class="external text external">"European Medicines Agency recommends approval of first two monoclonal-antibody biosimilars"</a> <a href="javascript:if(confirm('https://web.archive.org/web/20150217051925/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2013%2F06%2Fnews_detail_001837.jsp&mid=WC0b01ac058004d5c1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150217051925/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2013%2F06%2Fnews_detail_001837.jsp&mid=WC0b01ac058004d5c1'" tppabs="https://web.archive.org/web/20150217051925/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2013%2F06%2Fnews_detail_001837.jsp&mid=WC0b01ac058004d5c1" class="external text external">Archived</a><span> 2015-02-17 at the </span>Wayback Machine, European Medicines Agency, June 28, 2013</span></li><li id="cite_note-40"> <span id="mw-reference-text-cite_note-40" class="mw-reference-text"><cite id="CITEREFRockoff2013" class="citation news cs1">Rockoff, Jonathan D. (10 September 2013). <a href="javascript:if(confirm('https://web.archive.org/web/20170125062916/http://www.wsj.com/articles/SB10001424127887324094704579067360123704206  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170125062916/http://www.wsj.com/articles/SB10001424127887324094704579067360123704206'" tppabs="https://web.archive.org/web/20170125062916/http://www.wsj.com/articles/SB10001424127887324094704579067360123704206" class="external text external">"European Commission Approves Biosimilar of J&amp;J and Merck's Remicade"</a>. <i>The Wall Street Journal</i>. Archived from <span class="cs1-lock-subscription"><a href="javascript:if(confirm('https://www.wsj.com/articles/european-commission-approves-biosimilar-of-jj-and-mercks-remicade-1378844400  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.wsj.com/articles/european-commission-approves-biosimilar-of-jj-and-mercks-remicade-1378844400'" tppabs="https://www.wsj.com/articles/european-commission-approves-biosimilar-of-jj-and-mercks-remicade-1378844400" class="external text external">the original</a></span> on 25 January 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">1 March</span> 2020</span>.</cite></span></li><li id="cite_note-Remsima_EPAR-41"> <span id="mw-reference-text-cite_note-Remsima_EPAR-41" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/remsima  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/remsima'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/remsima" class="external text external">"Remsima EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">1 March</span> 2020</span>.</cite></span></li><li id="cite_note-Inflectra_EPAR-42"> <span id="mw-reference-text-cite_note-Inflectra_EPAR-42" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra" class="external text external">"Inflectra EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">1 March</span> 2020</span>.</cite></span></li><li id="cite_note-43"> <span id="mw-reference-text-cite_note-43" class="mw-reference-text"><cite id="CITEREFSerebrov" class="citation web cs1">Serebrov, Mari. <a href="javascript:if(confirm('http://www.bioworld.com/content/epirus-racks-its-first-biosimilar-approval-india-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.bioworld.com/content/epirus-racks-its-first-biosimilar-approval-india-0'" tppabs="http://www.bioworld.com/content/epirus-racks-its-first-biosimilar-approval-india-0" class="external text external">"Epirus racks up its first biosimilar approval in India"</a>. <i>BioWorld</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20141029213733/http://www.bioworld.com/content/epirus-racks-its-first-biosimilar-approval-india-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20141029213733/http://www.bioworld.com/content/epirus-racks-its-first-biosimilar-approval-india-0'" tppabs="https://web.archive.org/web/20141029213733/http://www.bioworld.com/content/epirus-racks-its-first-biosimilar-approval-india-0" class="external text external">Archived</a> from the original on 29 October 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">26 October</span> 2014</span>.</cite></span></li><li id="cite_note-44"> <span id="mw-reference-text-cite_note-44" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/news-events/press-announcements/fda-approves-inflectra-biosimilar-remicade  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/news-events/press-announcements/fda-approves-inflectra-biosimilar-remicade'" tppabs="https://www.fda.gov/news-events/press-announcements/fda-approves-inflectra-biosimilar-remicade" class="external text external">"FDA approves Inflectra, a biosimilar to Remicade"</a>. <i>U.S. Food and Drug Administration (FDA)</i> (Press release). 6 December 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191207001439/https://www.fda.gov/news-events/press-announcements/fda-approves-inflectra-biosimilar-remicade  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191207001439/https://www.fda.gov/news-events/press-announcements/fda-approves-inflectra-biosimilar-remicade'" tppabs="https://web.archive.org/web/20191207001439/https://www.fda.gov/news-events/press-announcements/fda-approves-inflectra-biosimilar-remicade" class="external text external">Archived</a> from the original on 7 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">6 December</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-45"> <span id="mw-reference-text-cite_note-45" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125544  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125544'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125544" class="external text external">"Inflectra: FDA-Approved Drugs"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 6 December 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191207001412/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125544  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191207001412/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125544'" tppabs="https://web.archive.org/web/20191207001412/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125544" class="external text external">Archived</a> from the original on 7 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">6 December</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-biib-46"> <span id="mw-reference-text-cite_note-biib-46" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.nasdaq.com/article/key-takeaways-from-biogens-q3-call-tecfidera-pipeline-biosimilars-cm699225/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nasdaq.com/article/key-takeaways-from-biogens-q3-call-tecfidera-pipeline-biosimilars-cm699225/'" tppabs="http://www.nasdaq.com/article/key-takeaways-from-biogens-q3-call-tecfidera-pipeline-biosimilars-cm699225/" class="external text external">"Key Takeaways from Biogen's Q3 Call: Tecfidera, Pipeline, Biosimilars"</a>. <i>nasdaq.com</i>. 27 October 2016. <a href="javascript:if(confirm('https://web.archive.org/web/20161028083846/http://www.nasdaq.com/article/key-takeaways-from-biogens-q3-call-tecfidera-pipeline-biosimilars-cm699225/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161028083846/http://www.nasdaq.com/article/key-takeaways-from-biogens-q3-call-tecfidera-pipeline-biosimilars-cm699225/'" tppabs="https://web.archive.org/web/20161028083846/http://www.nasdaq.com/article/key-takeaways-from-biogens-q3-call-tecfidera-pipeline-biosimilars-cm699225/" class="external text external">Archived</a> from the original on 28 October 2016.</cite></span></li><li id="cite_note-Flixabi_EPAR-47"> <span id="mw-reference-text-cite_note-Flixabi_EPAR-47" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi" class="external text external">"Flixabi EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-Zessly_EPAR-48"> <span id="mw-reference-text-cite_note-Zessly_EPAR-48" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/zessly  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/zessly'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/zessly" class="external text external">"Zessly EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-49"> <span id="mw-reference-text-cite_note-49" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.rxlist.com/remicade-drug.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.rxlist.com/remicade-drug.htm'" tppabs="http://www.rxlist.com/remicade-drug.htm" class="external text external">"Remicade (Infliximab): Side Effects, Interactions, Warning, Dosage &amp; Uses"</a>. <i>rxlist.com</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20091218222855/http://www.rxlist.com/remicade-drug.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20091218222855/http://www.rxlist.com/remicade-drug.htm'" tppabs="https://web.archive.org/web/20091218222855/http://www.rxlist.com/remicade-drug.htm" class="external text external">Archived</a> from the original on 18 December 2009.</cite></span></li><li id="cite_note-50"> <span id="mw-reference-text-cite_note-50" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://guidance.nice.org.uk/TA40/Guidance  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://guidance.nice.org.uk/TA40/Guidance'" tppabs="http://guidance.nice.org.uk/TA40/Guidance" class="external text external">"The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease - Guidance and guidelines - NICE"</a>. <i>guidance.nice.org.uk</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20100430172000/http://guidance.nice.org.uk/TA40/Guidance  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20100430172000/http://guidance.nice.org.uk/TA40/Guidance'" tppabs="https://web.archive.org/web/20100430172000/http://guidance.nice.org.uk/TA40/Guidance" class="external text external">Archived</a> from the original on 30 April 2010.</cite></span></li><li id="cite_note-51"> <span id="mw-reference-text-cite_note-51" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.nice.org.uk/guidance/ta329  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nice.org.uk/guidance/ta329'" tppabs="http://www.nice.org.uk/guidance/ta329" class="external text external">"Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy"</a>. <i>National Institute for Health and Care Excellence (NICE)</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20150306044422/http://www.nice.org.uk/guidance/ta329  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150306044422/http://www.nice.org.uk/guidance/ta329'" tppabs="https://web.archive.org/web/20150306044422/http://www.nice.org.uk/guidance/ta329" class="external text external">Archived</a> from the original on 6 March 2015.</cite></span></li><li id="cite_note-52"> <span id="mw-reference-text-cite_note-52" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20110903072031/http://www.medicareaustralia.gov.au/provider/pbs/drugs1/crohns.jsp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110903072031/http://www.medicareaustralia.gov.au/provider/pbs/drugs1/crohns.jsp#N10041'" tppabs="https://web.archive.org/web/20110903072031/http://www.medicareaustralia.gov.au/provider/pbs/drugs1/crohns.jsp#N10041" class="external text external">"Section 100 arrangements; only for infliximab"</a>. <i>medicareaustralia.gov.au</i>. Archived from <a href="javascript:if(confirm('http://www.medicareaustralia.gov.au/provider/pbs/drugs1/crohns.jsp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medicareaustralia.gov.au/provider/pbs/drugs1/crohns.jsp#N10041'" tppabs="http://www.medicareaustralia.gov.au/provider/pbs/drugs1/crohns.jsp#N10041" class="external text external">the original</a> on 3 September 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">20 August</span> 2011</span>.</cite></span></li><li id="cite_note-53"> <span id="mw-reference-text-cite_note-53" class="mw-reference-text">JNJ annual report, downloaded April 22, 2014. <cite class="citation web cs1"><a href="javascript:if(confirm('https://www.sec.gov/Archives/edgar/data/200406/000020040614000033/a2013122910-k.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.sec.gov/Archives/edgar/data/200406/000020040614000033/a2013122910-k.htm'" tppabs="https://www.sec.gov/Archives/edgar/data/200406/000020040614000033/a2013122910-k.htm" class="external text external">"Archived copy"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20160305020323/http://www.sec.gov/Archives/edgar/data/200406/000020040614000033/a2013122910-k.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160305020323/http://www.sec.gov/Archives/edgar/data/200406/000020040614000033/a2013122910-k.htm'" tppabs="https://web.archive.org/web/20160305020323/http://www.sec.gov/Archives/edgar/data/200406/000020040614000033/a2013122910-k.htm" class="external text external">Archived</a> from the original on 5 March 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">1 September</span> 2017</span>.</cite><span class="cs1-maint citation-comment">CS1 maint: archived copy as title (link)</span></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/infliximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/infliximab'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/infliximab" class="external text external">"Infliximab"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Merck_&amp;amp;_Co." style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Merck_&amp;amp;_Co." style="font-size:114%;margin:0 4em">Merck &amp; Co.</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Subsidiaries</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Cubist Pharmaceuticals</li>
<li>H. K. Mulford Company</li>
<li>Schering-Plough</li>
<li>Viralytics</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Schering-Plough</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Coppertone sign</li>
<li><a href="Desloratadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Desloratadine" title="Desloratadine">Desloratadine</a></li>
<li><a href="Ezetimibe.htm" tppabs="https://ptable.com/wiki/compounds/A/Ezetimibe" title="Ezetimibe">Ezetimibe</a></li>
<li>Ezetimibe/simvastatin</li>
<li><a href="Famciclovir.htm" tppabs="https://ptable.com/wiki/compounds/A/Famciclovir" title="Famciclovir">Famciclovir</a></li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li><a href="Loratadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Loratadine" title="Loratadine">Loratadine</a></li>
<li>Mometasone</li>
<li><a href="Rocuronium_bromide.htm" tppabs="https://ptable.com/wiki/compounds/A/Rocuronium_bromide" title="Rocuronium bromide">Rocuronium bromide</a></li>
<li><a href="Temozolomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Temozolomide" title="Temozolomide">Temozolomide</a></li>
<li>Tibolone</li>
<li><a href="Urofollitropin.htm" tppabs="https://ptable.com/wiki/compounds/A/Urofollitropin" title="Urofollitropin">Urofollitropin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Facilities</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Merck Headquarters Building</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Publications</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Merck Manual of Diagnosis and Therapy</li>
<li>The Merck Manuals</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="font-size:114%;margin:0 4em">Immunosuppressive drugs<span>&nbsp;</span>/ Immunosuppressants (L04)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(initiation)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Antimetabolites</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>purine synthesis inhibitors</i>
<ul><li><a href="Azathioprine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azathioprine" title="Azathioprine">Azathioprine</a></li>
<li><a href="Mycophenolic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Mycophenolic_acid" title="Mycophenolic acid">Mycophenolic acid</a></li></ul></li></ul>

<ul><li><i>pyrimidine synthesis inhibitors</i>
<ul><li><a href="Leflunomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Leflunomide" title="Leflunomide">Leflunomide</a></li>
<li>Teriflunomide</li></ul></li></ul>

<ul><li><i>antifolate</i>
<ul><li><a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">Methotrexate</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Macrolides/<br>other <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a> inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>FKBP/Cyclophilin/Calcineurin</i>
<ul><li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Ciclosporin" title="Ciclosporin">Ciclosporin</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li></ul></li></ul>

<ul><li>Abetimus</li>
<li>Gusperimus</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">IMiDs</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Lenalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Lenalidomide" title="Lenalidomide">Lenalidomide</a></li>
<li>Pomalidomide</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li><i>PDE4 inhibitor</i>
<ul><li>Apremilast</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(reception)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">IL-1 receptor antagonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Anakinra.htm" tppabs="https://ptable.com/wiki/compounds/A/Anakinra" title="Anakinra">Anakinra</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">mTOR</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Sirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Sirolimus" title="Sirolimus">Sirolimus</a></li>
<li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li>Ridaforolimus</li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li>
<li>Umirolimus</li>
<li>Zotarolimus</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Extracellular</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Antibody.htm" tppabs="https://ptable.com/wiki/compounds/A/Antibody" title="Antibody">Antibodies</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Monoclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Serum target<br>(noncellular)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Complement component 5</i>
<ul><li>Eculizumab</li></ul></li>
<li><i>TNF</i>
<ul><li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Afelimomab</li>
<li>Certolizumab pegol</li>
<li>Golimumab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li>Nerelimomab</li></ul></li>
<li><i>Interleukin 5</i>
<ul><li>Mepolizumab</li></ul></li>
<li><i>Immunoglobulin E</i>
<ul><li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li></ul></li></ul>

<ul><li><i>Interferon</i>
<ul><li>Faralimomab</li></ul></li></ul>

<ul><li><i>IL-6</i>
<ul><li>Elsilimomab</li></ul></li></ul>

<ul><li><i>IL-12 and IL-23</i>
<ul><li>Lebrikizumab</li>
<li>Ustekinumab</li></ul></li></ul>

<ul><li><i>IL-17A</i>
<ul><li>Secukinumab</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Cellular<br>target</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CD3</i>
<ul><li><a href="Muromonab-CD3.htm" tppabs="https://ptable.com/wiki/compounds/A/Muromonab-CD3" title="Muromonab-CD3">Muromonab-CD3</a></li>
<li>Otelixizumab</li>
<li>Teplizumab</li>
<li>Visilizumab</li></ul></li>
<li><i>CD4</i>
<ul><li>Clenoliximab</li>
<li>Keliximab</li>
<li>Zanolimumab</li></ul></li>
<li><i>CD11a</i>
<ul><li>Efalizumab</li></ul></li>
<li><i>CD18</i>
<ul><li>Erlizumab</li></ul></li>
<li><i>CD20</i>
<ul><li>Obinutuzumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li>Ocrelizumab</li>
<li>Pascolizumab</li></ul></li>
<li><i>CD23</i>
<ul><li>Gomiliximab</li>
<li>Lumiliximab</li></ul></li>
<li><i>CD40</i>
<ul><li>Teneliximab</li>
<li>Toralizumab</li></ul></li>
<li><i>CD62L/L-selectin</i>
<ul><li>Aselizumab</li></ul></li>
<li><i>CD80</i>
<ul><li>Galiximab</li></ul></li>
<li><i>CD147/Basigin</i>
<ul><li>Gavilimomab</li></ul></li>
<li><i>CD154</i>
<ul><li>Ruplizumab</li></ul></li></ul>

<ul><li><i>BLyS</i>
<ul><li>Belimumab</li>
<li>Blisibimod</li></ul></li>
<li><i>CTLA-4</i>
<ul><li>Ipilimumab</li>
<li>Tremelimumab</li></ul></li>
<li><i>CAT</i>
<ul><li>Bertilimumab</li>
<li>Lerdelimumab</li>
<li>Metelimumab</li></ul></li>
<li><i>Integrin</i>
<ul><li>Natalizumab</li>
<li>Vedolizumab</li></ul></li>
<li><i>Interleukin-6 receptor</i>
<ul><li>Tocilizumab</li></ul></li>
<li><i>LFA-1</i>
<ul><li>Odulimomab</li></ul></li></ul>

<ul><li><i>IL-2 receptor/CD25</i>
<ul><li><a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li>Inolimomab</li></ul></li></ul>

<ul><li><i>T-lymphocyte</i> (Zolimomab aritox)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Atorolimumab</li>
<li>Cedelizumab</li>
<li>Fontolizumab</li>
<li>Maslimomab</li>
<li>Morolimumab</li>
<li>Pexelizumab</li>
<li>Reslizumab</li>
<li>Rovelizumab</li>
<li>Siplizumab</li>
<li>Talizumab</li>
<li>Telimomab aritox</li>
<li>Vapaliximab</li>
<li>Vepalimomab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Polyclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anti-thymocyte globulin</li>
<li>Anti-lymphocyte globulin</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">-cept (Fusion)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CTLA-4</i>
<ul><li>Abatacept</li>
<li>Belatacept</li></ul></li>
<li><i>TNF inhibitor</i>
<ul><li><a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">Etanercept</a></li>
<li>Pegsunercept</li></ul></li>
<li>Aflibercept</li>
<li><a href="Alefacept.htm" tppabs="https://ptable.com/wiki/compounds/A/Alefacept" title="Alefacept">Alefacept</a></li>
<li>Rilonacept</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_the_immune_system" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2" style="text-align:center;"><div id="Monoclonal_antibodies_for_the_immune_system" style="font-size:114%;margin:0 4em">Monoclonal antibodies for the immune system</div></th></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Immune system</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Human</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Immunosuppression</i>: Abrilumab</li>
<li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Anifrolumab<sup>†</sup></li>
<li>Atorolimumab</li>
<li>Avelumab</li>
<li>Belimumab</li>
<li>Bleselumab</li>
<li>Brodalumab</li>
<li>Camidanlumab tesirine</li>
<li>Carlumab</li>
<li>Cemiplimab</li>
<li>Dupilumab</li>
<li>Eldelumab</li>
<li>Emapalumab<sup>†</sup></li>
<li>Fresolimumab</li>
<li>Golimumab</li>
<li>Ianalumab<sup>†</sup></li>
<li>Lanadelumab</li>
<li>Lenzilumab</li>
<li>Lerdelimumab</li>
<li>Lirilumab</li>
<li>Mavrilimumab</li>
<li>Metelimumab</li>
<li>Morolimumab</li>
<li>Namilumab</li>
<li>Oleclumab</li>
<li>Oxelumab§</li>
<li>Pamrevlumab</li>
<li>Placulumab</li>
<li>Relatlimab<sup>†</sup></li>
<li>Sarilumab</li>
<li>Sifalimumab</li>
<li>Tabalumab</li>
<li>Tezepelumab<sup>†</sup></li>
<li>Ulocuplumab</li>
<li>Varlilumab</li></ul>

<ul><li><i>Immune activation</i>: Ipilimumab</li>
<li>Atezolizumab</li>
<li>Durvalumab</li>
<li>Nivolumab</li>
<li>Pembrolizumab</li>
<li>Tremelimumab<sup>†</sup></li>
<li>Urelumab</li></ul>

<ul><li><i>Other</i>: Bertilimumab</li>
<li>Zanolimumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Mouse</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Afelimomab</li>
<li>Elsilimomab</li>
<li>Faralimomab</li>
<li>Gavilimomab</li>
<li>Inolimomab</li>
<li>Maslimomab</li>
<li>Nerelimomab</li>
<li>Odulimomab</li>
<li>Telimomab aritox</li>
<li>Vepalimomab</li>
<li>Zolimomab aritox</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chimeric</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Andecaliximab<sup>†</sup></li>
<li><a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li>Clenoliximab</li>
<li>Galiximab</li>
<li>Gomiliximab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li>Keliximab</li>
<li>Lumiliximab</li>
<li>Priliximab</li>
<li>Teneliximab</li>
<li>Vapaliximab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Humanized</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Immunosuppressive:</i> Aselizumab</li>
<li>Apolizumab<sup>§</sup></li>
<li>Benralizumab</li>
<li>Camrelizumab<sup>†</sup></li>
<li>Cedelizumab</li>
<li>Certolizumab pegol</li>
<li>Crizanlizumab<sup>†</sup></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li>Dostarlimab<sup>†</sup></li>
<li>Eculizumab</li>
<li>Efalizumab<sup>‡</sup></li>
<li>Epratuzumab</li>
<li>Erlizumab</li>
<li>Etrolizumab<sup>†</sup></li>
<li>Fontolizumab</li>
<li>Inebilizumab</li>
<li>Itolizumab</li>
<li>Lampalizumab<sup>†</sup></li>
<li>Letolizumab</li>
<li>Ligelizumab<sup>†</sup></li>
<li>Lulizumab pegol</li>
<li>Mepolizumab</li>
<li>Mogamulizumab</li>
<li>Natalizumab</li>
<li>Ocrelizumab</li>
<li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li>
<li>Ozoralizumab</li>
<li>Pascolizumab</li>
<li>Pateclizumab</li>
<li>Pembrolizumab</li>
<li>Pexelizumab</li>
<li>Pidilizumab</li>
<li>Plozalizumab</li>
<li>PRO 140<sup>†</sup></li>
<li>Quilizumab</li>
<li>Ravulizumab</li>
<li>Reslizumab</li>
<li>Rontalizumab</li>
<li>Rovelizumab</li>
<li>Ruplizumab</li>
<li>Samalizumab</li>
<li>Satralizumab</li>
<li>Siplizumab</li>
<li>Spartalizumab<sup>†</sup></li>
<li>Talizumab</li>
<li>Teplizumab</li>
<li>Tislelizumab</li>
<li>Tocilizumab</li>
<li>Toralizumab</li>
<li>Tregalizumab</li>
<li>Vatelizumab</li>
<li>Vedolizumab</li>
<li>Visilizumab</li>
<li>Vobarilizumab</li>
<li>TGN1412<sup>§</sup><br><i>Non-immunosuppressive:</i> Ibalizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chimeric + humanized<br></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Otelixizumab</li>
<li>Sutimlimab<sup>†</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Interleukin</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Human</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Bermekimab</li>
<li>Brazikumab</li>
<li>Briakinumab</li>
<li>Canakinumab</li>
<li>Fezakinumab</li>
<li>Fletikumab</li>
<li>Guselkumab</li>
<li>Secukinumab</li>
<li>Sirukumab</li>
<li>Tralokinumab<sup>†</sup></li>
<li>Ustekinumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Humanized</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anrukinzumab</li>
<li>Bimekizumab<sup>†</sup></li>
<li>Clazakizumab</li>
<li>Gevokizumab</li>
<li>Ixekizumab</li>
<li>Mirikizumab<sup>†</sup></li>
<li>Lebrikizumab</li>
<li>Olokizumab<sup>†</sup></li>
<li>Perakizumab</li>
<li>Risankizumab</li>
<li>Tildrakizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Veterinary</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Lokivetmab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Inflammatory lesions</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="Mouse" scope="row" class="navbox-group" style="width:1%;text-align:center;">Mouse</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Besilesomab</li>
<li>Fanolesomab<sup>‡</sup></li>
<li>Lemalesomab</li>
<li>Sulesomab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="text-align:center;;background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>











<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-13" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Infliximab&oldid=972636916  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Infliximab&oldid=972636916'" tppabs="https://en.wikipedia.org/wiki/?title=Infliximab&oldid=972636916">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>